Ignite Creation Date:
2024-05-06 @ 10:24 AM
Last Modification Date:
2024-10-26 @ 12:30 PM
Study NCT ID:
NCT03255512
Status:
COMPLETED
Last Update Posted:
2021-12-29
First Post:
2017-08-03
Brief Title:
Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients
Sponsor:
Bayer
Organization:
Bayer
Study Overview
Official Title:
Multi-center Randomized Placebo-controlled Double-blind Group Comparison Study to Investigate Safety Tolerability and Blood Pressure of 25 mg 50 mg and 10 mg Vericiguat Each Given Over 14 3 Days Together With Isosorbite Mononitrate ISMN 60 mg Extended Release Formulation After a Pretreatment Phase ISMN-starting Dose 30 mg in Stable Coronary Artery Disease CAD Patients With or Without Heart Failure Aged 30 to 80 Years - Vericiguat ISOsoRbite Mononitrate Interaction VISOR Study
Status:
COMPLETED
Status Verified Date:
2021-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VISOR
Brief Summary:
This study is intended to investigate the pharmacodynamic drug-drug interaction as well as the safety and tolerability of isosorbite mononitrate and vericiguat in patients with stable coronary artery disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2016-005178-36 | EUDRACT_NUMBER | None | None |